What does ARQUENNES PHARMA do?

ARQUENNES PHARMA is a pharmacy in Seneffe. Public Limited, started on 7 January 1991, 1 establishment.

What is the address of ARQUENNES PHARMA?

The registered office of ARQUENNES PHARMA is located at Chaussée de Nivelles 141 box 2, 7181 Seneffe.

Is ARQUENNES PHARMA still active?

Yes. According to the CBE (30 October 2026) ARQUENNES PHARMA is active, legal situation “Normale toestand”, started on 7 January 1991.

Is ARQUENNES PHARMA registered on Peppol?

Yes, ARQUENNES PHARMA is registered on the Peppol network with ID 0208:0442964356.

What is the enterprise number of ARQUENNES PHARMA?

The enterprise number of ARQUENNES PHARMA is BE0442964356.

When was ARQUENNES PHARMA founded?

ARQUENNES PHARMA was founded on 7 January 1991.

Who are the directors of ARQUENNES PHARMA?

According to the 2025 annual accounts, the directors of ARQUENNES PHARMA are: GFCS SCS, Nadine Demeulemeester, Anne Dejardin, EGUIMAX SCS.

Is ARQUENNES PHARMA a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 7 January 1991; 5 annual accounts filed, latest fiscal year 2025; 4 directors known from the annual account.

How much profit did ARQUENNES PHARMA make in 2025?

ARQUENNES PHARMA posted a profit after taxes of € 132,377 in financial year 2025.

What is the revenue of ARQUENNES PHARMA?

As a small company, ARQUENNES PHARMA is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 462,062.

How much does an employee at ARQUENNES PHARMA earn?

The average wage cost per full-time employee at ARQUENNES PHARMA was € 71,900 in 2025: staff costs of € 287,420 for 4 FTE, according to the annual account at the National Bank. That is the employer's cost, not net pay.

How many employees does ARQUENNES PHARMA have?

According to the 2025 annual accounts, ARQUENNES PHARMA has 4 full-time equivalents (FTE).

ARQUENNES PHARMA (Public Limited) - Seneffe

Dossier ARQUENNES PHARMA, printed on 30 October 2026 from databakkes.be/en/0442964356/arquennes-pharma. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

ARQUENNES PHARMA from Seneffe, company number BE0442964356, closed financial year 2025 with a result of € 132,377 after tax. For that financial year ARQUENNES PHARMA recorded a gross margin of € 462,062 and equity of € 238,406. Compared with financial year 2024, the result moved from € 121,830 to € 132,377. Profitable, and profit is growing. The buffer is growing. Debts are under control. The most recent annual accounts were filed with the National Bank of Belgium on August 31, 2026.

What it is worth Growing

€ 238,406

▲ 1% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 132,377

▲ 9% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 197,203

▼ 9% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Pays out

€ 130,000 paid out

98 % of the profit went to the shareholders, the rest stayed in the company.

People and assets in 2025

Full-time equivalents

▼ 0.3 vs 2024

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 287,420

▼ 2% vs 2024

€ 71,900 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 23,362

Book value of vehicles, furniture and equipment.

Debts at end 2025

Bank debt ≈ 3 years to go The accounts give the long-term loan and the part due within the year. The remainder divided by that part is the number of years at an equal pace; a new loan or early repayment changes it.

€ 82,223

▼ 24% vs 2024

€ 26,667 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.

Owed to suppliers

€ 46,496

Supplier invoices still open on the last day of the fiscal year.

Taxes and wages

€ 173,776

▲ 6% vs 2024

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year Download key figures (CSV)
	2022	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 396,943 Gross margin 2022: € 396,943 First fiscal year in the series	€ 427,502 Gross margin 2023: € 427,502 ▲ 8% vs 2022 (€ 396,943) Favourable step	€ 483,106 Gross margin 2024: € 483,106 ▲ 13% vs 2023 (€ 427,502) Favourable step	€ 462,062 Gross margin 2025: € 462,062 ▼ 4% vs 2024 (€ 483,106) Unfavourable step	▼ 4%
Profit after taxes	€ 67,400 Profit after taxes 2022: € 67,400 First fiscal year in the series	€ 43,515 Profit after taxes 2023: € 43,515 ▼ 35% vs 2022 (€ 67,400) Unfavourable step	€ 121,830 Profit after taxes 2024: € 121,830 ▲ 180% vs 2023 (€ 43,515) Favourable step	€ 132,377 Profit after taxes 2025: € 132,377 ▲ 9% vs 2024 (€ 121,830) Favourable step	▲ 9%
Equity	€ 230,684 Equity 2022: € 230,684 First fiscal year in the series	€ 234,199 Equity 2023: € 234,199 ▲ 2% vs 2022 (€ 230,684) Favourable step	€ 236,029 Equity 2024: € 236,029 ▲ 1% vs 2023 (€ 234,199) Favourable step	€ 238,406 Equity 2025: € 238,406 ▲ 1% vs 2024 (€ 236,029) Favourable step	▲ 1%
Total debts	€ 545,267 Total debts 2022: € 545,267 First fiscal year in the series	€ 507,285 Total debts 2023: € 507,285 ▼ 7% vs 2022 (€ 545,267) Favourable step	€ 573,620 Total debts 2024: € 573,620 ▲ 13% vs 2023 (€ 507,285) Unfavourable step	€ 474,162 Total debts 2025: € 474,162 ▼ 17% vs 2024 (€ 573,620) Favourable step	▼ 17%
Cash	€ 161,814 Cash 2022: € 161,814 First fiscal year in the series	€ 152,494 Cash 2023: € 152,494 ▼ 6% vs 2022 (€ 161,814) Unfavourable step	€ 217,166 Cash 2024: € 217,166 ▲ 42% vs 2023 (€ 152,494) Favourable step	€ 197,203 Cash 2025: € 197,203 ▼ 9% vs 2024 (€ 217,166) Unfavourable step	▼ 9%
Land & buildings	€ 198,417 Land & buildings 2022: € 198,417 First fiscal year in the series	€ 187,394 Land & buildings 2023: € 187,394 ▼ 6% vs 2022 (€ 198,417) Unchanged	€ 176,370 Land & buildings 2024: € 176,370 ▼ 6% vs 2023 (€ 187,394) Unchanged	€ 165,347 Land & buildings 2025: € 165,347 ▼ 6% vs 2024 (€ 176,370) Unchanged	▼ 6%
Retained profit	€ 168,684 Retained profit 2022: € 168,684 First fiscal year in the series	€ 172,199 Retained profit 2023: € 172,199 ▲ 2% vs 2022 (€ 168,684) Favourable step	€ 174,029 Retained profit 2024: € 174,029 ▲ 1% vs 2023 (€ 172,199) Favourable step	€ 176,406 Retained profit 2025: € 176,406 ▲ 1% vs 2024 (€ 174,029) Favourable step	▲ 1%
Dividend	€ 65,000 Dividend 2022: € 65,000 First fiscal year in the series	€ 40,000 Dividend 2023: € 40,000 ▼ 38% vs 2022 (€ 65,000) Unchanged	€ 120,000 Dividend 2024: € 120,000 ▲ 200% vs 2023 (€ 40,000) Unchanged	€ 130,000 Dividend 2025: € 130,000 ▲ 8% vs 2024 (€ 120,000) Unchanged	▲ 8%
Bank debt	€ 174,127 Bank debt 2022: € 174,127 First fiscal year in the series	€ 135,556 Bank debt 2023: € 135,556 ▼ 22% vs 2022 (€ 174,127) Favourable step	€ 108,889 Bank debt 2024: € 108,889 ▼ 20% vs 2023 (€ 135,556) Favourable step	€ 82,223 Bank debt 2025: € 82,223 ▼ 24% vs 2024 (€ 108,889) Favourable step	▼ 24%
Balance sheet total	€ 775,951 Balance sheet total 2022: € 775,951 First fiscal year in the series	€ 741,484 Balance sheet total 2023: € 741,484 ▼ 4% vs 2022 (€ 775,951) Unchanged	€ 809,649 Balance sheet total 2024: € 809,649 ▲ 9% vs 2023 (€ 741,484) Unchanged	€ 712,567 Balance sheet total 2025: € 712,567 ▼ 12% vs 2024 (€ 809,649) Unchanged	▼ 12%
Employees (FTE)	4.2 Employees (FTE) 2022: 4.2 First fiscal year in the series	4.2 Employees (FTE) 2023: 4.2 Unchanged (4.2) Unchanged	4.3 Employees (FTE) 2024: 4.3 ▲ 0.1 vs 2023 (4.2) Unchanged	4 Employees (FTE) 2025: 4 ▼ 0.3 vs 2024 (4.3) Unchanged	▼ 0.3

Key figures of ARQUENNES PHARMA, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to ARQUENNES PHARMA?

What happened at ARQUENNES PHARMA in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Aug 31, 2026 New annual accounts for financial year 2025: profit of € 132,377 (▲ 9% vs 2024). filed late Source: NBB ↗
Feb 4, 1991 New establishment in Seneffe. KBO
Jan 7, 1991 Start of the company according to the CBE. KBO

In short

From € 67,400 profit in 2022 to € 132,377 profit in 2025.

Paid € 10,587 in corporate taxes since 2022.

Best year ever: 2025, with € 132,377 profit.

On average € 115,500 of value added per employee in 2025.

Original PDFs at the National Bank ↗

Management

GFCS SCS Nadine Demeulemeester Anne Dejardin EGUIMAX SCS

ACLOT PHARMA

ARQUENNES PHARMA

Behind ARQUENNES PHARMA are GFCS SCS, Nadine Demeulemeester, Anne Dejardin and EGUIMAX SCS. GFCS SCS is also behind ACLOT PHARMA. Nadine Demeulemeester is also behind ACLOT PHARMA. EGUIMAX SCS is also behind ACLOT PHARMA.

Directors

According to the 2025 annual accounts

GFCS SCS

Director · represented by ALEXANDRE DEHAYE

Also active at: ACLOT PHARMA

Nadine Demeulemeester

Director

Also active at: ACLOT PHARMA

Anne Dejardin

Managing director

EGUIMAX SCS

Director · represented by Philippe Dehaye

Also active at: ACLOT PHARMA

Establishments

Establishment units

Physical locations of this company

Registered office

Chaussée de Nivelles 141 box 2

7181 Seneffe

Who else lives here?

A building full of entrepreneurs or one very busy letterbox? Another 1 companies are registered at this address.

All companies at this address →

TENAGLIA MATHILDE

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number

0442.964.356

VAT number

BE 0442.964.356

Registered office

Chaussée de Nivelles 141 bus 2, 7181 Seneffe

Names & denominations

ARQUENNES PHARMA

Enterprise type

Rechtspersoon

Legal form

Public limited company

Legal situation

Normale toestand

Start date

7 January 1991

Peppol

Active · Active since 29 Jun 2026

Activities · NACE

Detailhandel in farmaceutische producten

Apothekers

View on CBE Public ↗ Annual accounts (NBB) ↗

ARQUENNES PHARMA

Financials

What happened to ARQUENNES PHARMA?

Management

Directors

Establishments

Establishment units

Who else lives here?

Details

Frequently asked questions